Tokita K - Search Results

1

[Detection of BCR-ABL1 chimeric gene-positive neutrophils in a patient with mixed phenotype acute leukemia].

Nagasawa F, Nakamura Y, Tokita K, Takahashi W, Iso H, Arai H, Tsurumi S, Handa T, Nakamura Y, Nakamura Y, Sasaki K, Mitani K. Nagasawa F, et al. Among authors: tokita k. Rinsho Ketsueki. 2013 Nov;54(11):2074-8. Rinsho Ketsueki. 2013. PMID: 24305542 Japanese.

2

[Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy].

Tadokoro J, Arai Y, Tokita K, Iso H, Nakamura Y, Maki K, Sasaki K, Mitani K. Tadokoro J, et al. Among authors: tokita k. Rinsho Ketsueki. 2007 Jan;48(1):61-3. Rinsho Ketsueki. 2007. PMID: 17313078 Japanese.

3

[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].

Takahashi W, Nakamura Y, Tadokoro J, Handa T, Arai H, Tokita K, Iso H, Tsurumi S, Sasaki K, Maki K, Mitani K. Takahashi W, et al. Among authors: tokita k. Rinsho Ketsueki. 2012 Jan;53(1):71-7. Rinsho Ketsueki. 2012. PMID: 22374527 Clinical Trial. Japanese.

4

[Inv(16)-type acute myeloid leukemia with repeated skin infiltration without bone marrow relapse before and after allogeneic hematopoietic stem cell transplantation].

Tokita K, Takahashi W, Arai H, Handa T, Nakamura Y, Maki K, Sasaki K, Mitani K. Tokita K, et al. Rinsho Ketsueki. 2013 Dec;54(12):2203-6. Rinsho Ketsueki. 2013. PMID: 24452154 Japanese.

5

Chronic myelogenous leukemia in chronic phase transforming into acute leukemia under treatment with dasatinib 4 months after diagnosis.

Nakamura Y, Tokita K, Nagasawa F, Takahashi W, Nakamura Y, Sasaki K, Ichikawa M, Mitani K. Nakamura Y, et al. Among authors: tokita k. Int J Hematol. 2016 Mar;103(3):348-53. doi: 10.1007/s12185-015-1909-7. Epub 2015 Dec 12. Int J Hematol. 2016. PMID: 26662559

6

[Systemic organ invasion accompanied by immunophenotypic change observed in extraosseous plasmacytoma].

Tokita K, Nakamura Y, Iso H, Nakamura Y, Sasaki K, Mitani K. Tokita K, et al. Rinsho Ketsueki. 2016 Jan;57(1):56-9. doi: 10.11406/rinketsu.57.56. Rinsho Ketsueki. 2016. PMID: 26861106 Japanese.

7

PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma.

Nakamura F, Arai H, Tokita K, Furuichi S, Sugita-Nagasawa F, Takahashi W, Handa T, Iso H, Tadokoro J, Tsurumi S, Nakamura Y, Nakamura Y, Sasaki K, Seo S, Ichikawa M, Mitani K. Nakamura F, et al. Among authors: tokita k. Leuk Lymphoma. 2021 Jan;62(1):239-242. doi: 10.1080/10428194.2020.1817442. Epub 2020 Sep 11. Leuk Lymphoma. 2021. PMID: 32914680 No abstract available.

8

RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.

Tokita K, Maki K, Mitani K. Tokita K, et al. Cancer Sci. 2007 Nov;98(11):1752-7. doi: 10.1111/j.1349-7006.2007.00597.x. Cancer Sci. 2007. PMID: 17894555 Free PMC article.

9

Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.

Tokita K, Maki K, Tadokoro J, Nakamura Y, Arai Y, Sasaki K, Eguchi-Ishimae M, Eguchi M, Mitani K. Tokita K, et al. Leukemia. 2007 Jan;21(1):190-2. doi: 10.1038/sj.leu.2404397. Epub 2006 Nov 23. Leukemia. 2007. PMID: 17122866 No abstract available.

10

[EXPERIMENTAL STUDIES ON DIATHESIS AND CANCER. VI. EXPERIMENTS ON RESISTANCE TO YOSHIDA SARCOMA PRETREATED WITH HORSE SERUM AND NRES IN S.D. RATS].

TOKITA K, ITO R, TOSAKA K, NAGATA K, AYABE M, UNEMOTO M, NAKAMURA Y. TOKITA K, et al. Nihon Yakurigaku Zasshi. 1963 Nov 20;59:415-27. Nihon Yakurigaku Zasshi. 1963. PMID: 14104200 Japanese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters